SARS Cov_2 Incidence of Healthy Health Workers

NCT04845880 | Completed

• 1 other identifier: KA20/449
• Study Type: interventional
• Target: 182
• Locations: 1 country
• Sites: 1

Brief Summary

Since the severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) first emerged in Wuhan, China, on 12 December 2019, it has spread rapidly across the world and developed into a pandemic. The pandemic has affected over 100 countries and regions, with over 132 million confirmed cases of COVID-19. The rapid spread of SARS-CoV-2 has caused considerable harm to public health and the economy. Alongside other laboratory tests and clinical findings of the COVID-19 infection, serological testing may be beneficial for epidemiological monitoring and outbreak control. The determination of antibodies enables confirmation of the SARS-CoV-2 infection in asymptomatic patients in addition to those with typical symptoms. In this study, we aimed to determine the SARS-CoV-2 seroprevalence and the IgG antibody levels among healthcare workers who frequently encountered COVID-19 patients in our hospital.

Conditions

SARS COV-2 IgG Levels on Health Workers

Outcome Measures

Primary Outcomes (1)

• Evaluation of IgG Neutralizing Antibodies to SARS-CoV-2 Among Healthcare Workers Who Frequently Encountered COVID-19 patients in Our Hospital

  Determining antibody levels and seroprevalence of healthy healthcare workers

  6 months

Study Arms (1)

SARS Cov_2 Incidence of Healthy Health Workers

OTHER

Diagnostic Test: Spike protein (S) or the nucleocapsid (N) of SARS-CoV-2

Interventions

Spike protein (S) or the nucleocapsid (N) of SARS-CoV-2 DIAGNOSTIC_TEST

Blood level of spike protein (S) or the nucleocapsid (N) of SARS-CoV-2

SARS Cov_2 Incidence of Healthy Health Workers

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Healthy Health Workers - SARS COV-2 PCR (-)

You may not qualify if:

• Health Workers - SARS COV-2 PCR (+) Pregnancy Autoimmune diseases Received immunosuppressive therapy

Sponsors & Collaborators

• Baskent University: lead
• Hikmet Eda Aliskan: collaborator
• Hatice Hale Gumus: collaborator
• Ilker Odemis: collaborator
• Zuhal Ekici Unsal: collaborator

Study Sites (1)

Adana Dr. Turgut Noyan Application and Research Center

Adana, Turkey (Türkiye)

Location

Related Publications (2)

• Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, Dai J, Sun Q, Zhao F, Qu J, Yan F. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020 Apr;80(4):388-393. doi: 10.1016/j.jinf.2020.02.016. Epub 2020 Feb 26.

  PMID: 32112884 BACKGROUND

• Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 Feb 15;395(10223):514-523. doi: 10.1016/S0140-6736(20)30154-9. Epub 2020 Jan 24.

  PMID: 31986261 BACKGROUND

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SCREENING
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Specialist Doctor

Study Record Dates

• First Submitted: April 13, 2021
• First Posted: April 15, 2021
• Study Start: October 1, 2020
• Primary Completion: March 1, 2021
• Study Completion: April 1, 2021
• Last Updated: April 15, 2021

Record last verified: 2021-04

Locations

TU (1)